Not recruitingEUCTR 2022-000430-42

Long-term safety of aticaprant added to antidepressants in adults with depression

About this title

A study to evaluate if aticaprant added to a current antidepressant and given up to one year is safe and would help improve depression.

Read the official source — EUCTR 2022-000430-42

This historical record does not confirm current site availability.

Historical research recordMultiple countries

The study in practice

Understand this study

What is this study about?

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments. Check the source details below for country statuses and any transfer to CTIS.

Who could participate?

This study is for people with depression. Other eligibility criteria apply.

Listed locations: Alken and 78 more locationsSee all locations and recruitment
Study phase: Phase 3

Get this study by email

What to know before participating

A point to clarify

This is historical registry information. What is the current study status and protocol?

Study clarity

Things to check before joining

Study start dateNot clearly listed

Recruitment status: Not recruiting
Enrollment listed in the registry: 840
Sponsor: Janssen-Cilag International NV
Sponsor type: Unknown or unclear
Study type: Drug
Intervention type: Medication / drug
Study phase: Phase 3
Locations: France, Belgium, Bulgaria, ...
Age range: Not clearly listed
Official registry ID: EUCTR 2022-000430-42
Official title: Show the full official title
An Open-label, Long-term, Safety and Efficacy Study of Aticaprant as Adjunctive Therapy in Adult and Elderly Participants With Major Depressive Disorder (MDD)

Recruitment & locations

Not recruiting

Alken, Belgium · Brussels, Belgium · Duffel, Belgium

61 more locations

Sint-Niklaas, Belgium
Cherven Bryag, Bulgaria
Kirdzhali, Bulgaria
Plovdiv, Bulgaria
Ruse, Bulgaria
Sofia, Bulgaria
Sofiya, Bulgaria
Varna, Bulgaria
Veliko Tirnovo, Bulgaria
Klecany, Czechia
Plzen 3, Czechia
Prague, Czechia
Prague 10, Czechia
Prague 5, Czechia
Praha 9, Czechia
Brest, France
Clermont Ferrand Cedex 1, France
Douai, France
Nantes, France
Paris, France
Tours, France
Budapest, Hungary
Budapest III, Hungary
Gyongyos, Hungary
Kalocsa, Hungary
Pecs, Hungary
Szekszard, Hungary
Bergamo, Italy
Catanzaro, Italy
Lecce, Italy
Milan, Italy
Siena, Italy
Belchatow, Poland
Białystok, Poland
Bydgoszcz, Poland
Gdansk, Poland
Katowice, Poland
Lodz, Poland
Poznan, Poland
Suchy Las, Poland
Torun, Poland
Braga, Portugal
Lisbon, Portugal
Banská Bystrica, Slovakia
Bojnice, Slovakia
Kosice, Slovakia
Kosice - Zapad, Slovakia
Liptovsky Mikulas, Slovakia
Rimavska Sobota, Slovakia
Stare Mesto, Slovakia
Vranov Nad Toplou, Slovakia
Barcelona, Spain
Madrid, Spain
Ponferrada, Spain
Sabadell, Spain
Vigo, Spain
Vitoria-Gasteiz, Spain
Goteborg, Sweden
Lund, Sweden
Stockholm, Sweden
Czechia

Registry details

Original registry record

Current country statuses

Belgium — Ended
Bulgaria — Ended
Czechia — Ended
France — Ended
Hungary — Ended
Italy — Ended
Poland — Ended
Portugal — Ended
Slovakia — Ended
Spain — Ended
Sweden — Ended

Historical country statuses

Belgium — Trial now transitioned
Bulgaria — Trial now transitioned
Czechia — Trial now transitioned
Spain — Ongoing
France — Trial now transitioned
Hungary — Trial now transitioned
Poland — Trial now transitioned
Portugal — Trial now transitioned
Sweden — Trial now transitioned
Slovakia — Trial now transitioned

Interested in joining this study?

FAQ

Questions about this study

Who is behind this study?

The study sponsor is Janssen-Cilag International NV.

Who can participate?

This study is for people with depression. Other eligibility criteria apply.

Is this study still recruiting?

The registry lists this study as not recruiting.

Want to explore more studies?

Explore studies